Jeremy Bray, a 30-year-old with Type 2 spinal muscular atrophy, expressed disappointment after Manitoba’s Health Minister Uzoma Asagwara refused to fund his life-sustaining treatment with the drug risdiplam, despite his reported improvements. After Roche ended free coverage, Bray had hoped the NDP government would reverse its decision, citing potential benefits. His father and advocates criticize the government’s stance as financially motivated, noting other provinces have approved similar treatments. Asagwara stated they would work with Canada’s Drug Agency to seek a review but maintained that they would not overrule its recommendations.
